Flugalin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flugalin

Property Description
Active ingredient Flurbiprofen
Form Oromucosal spray (Solution for oral use)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Localized relief of sore throat/pharyngeal pain
Origin Synthetic (Propionic acid derivative)

What Type of Medicine is Flugalin?

Flugalin is a synthetic medicinal product containing the active ingredient Flurbiprofen, which is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification places it within the propionic acid derivative chemical family, establishing its core identity as an agent developed to manage inflammation and pain. The active compound, Flurbiprofen, is clinically recognized for its potent analgesic (pain-relieving) and anti-inflammatory activities.

Flurbiprofen functions primarily as a cyclooxygenase inhibitor, a mechanism that accounts for its capability to reduce chemical mediators responsible for inflammation and pain. The drug's fundamental property is its ability to block these critical chemical pathways.


Composition and Form: The Oromucosal Spray

Flugalin is distinguished by its formulation as an oromucosal spray, which is a solution for oral use intended for topical administration onto the mucosal surfaces of the throat. This product is a single-ingredient product (monoseptic), delivered in an aqueous or water-based vehicle, ensuring the therapeutic focus is solely on the properties of Flurbiprofen.

This specific form is a key differentiator from standard systemic NSAID tablets. Flurbiprofen is characterized by high permeability when applied in this manner, allowing the active compound to concentrate locally in the target pharyngeal tissues for efficient symptomatic relief.


General Purpose: Targeted Anti-Inflammatory Action

The primary purpose of Flugalin is to provide localized relief from the pain and discomfort associated with oropharyngeal inflammation, most commonly identified as a sore throat or pharyngitis. The medicine's action leverages the dual capability of the NSAID derivative. By focusing its anti-inflammatory and analgesic effect directly on the irritated tissues via topical administration, the product addresses both the pain and the underlying swelling, offering a targeted solution for short-term localized symptoms.

Regulatory References

  1. NIH LiverTox entry for Flurbiprofen

What side effects are possible with Flugalin?

Possible Side Effects and Safety Information

Flugalin is associated with risks typical of its drug class, which are detailed in official governmental regulatory labeling. These warnings address the potential for serious, life-threatening events involving the cardiovascular and gastrointestinal systems.

Serious and Clinically Significant Risks

Cardiovascular Thrombotic Events: Regulatory warnings highlight that Flugalin may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with the duration of use and is higher in patients with pre-existing heart disease or associated risk factors. This risk can begin early in treatment.

Gastrointestinal Adverse Events: The drug carries a serious risk of gastrointestinal inflammation, bleeding, ulceration, and perforation of the stomach or intestines. These events can occur without warning symptoms and may also be fatal. Patients with a history of GI disease are at increased risk.

Other Serious Adverse Reactions: These include nephrotoxicity (kidney damage), which may lead to acute kidney injury; severe hepatic (liver) injury; hypertension (high blood pressure); and anaphylactic reactions (severe allergic reactions).

Common Adverse Reactions

Commonly reported reactions often involve the gastrointestinal system and nervous system. These may include abdominal pain, nausea, diarrhea, dyspepsia (heartburn), constipation, headache, dizziness, and somnolence (drowsiness). Edema (fluid retention or swelling) is also a documented common side effect.

Safety Considerations

Restrictions on Use: Flugalin is generally restricted or contraindicated in patients with severe uncontrolled heart failure, recent myocardial infarction, active GI bleeding or perforation, and severe renal impairment. Caution is required in the elderly and in patients with asthma sensitive to aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Pregnancy: Regulatory information advises avoiding the use of this drug class in pregnant women at 20 weeks gestation or later due to the documented potential for fetal renal dysfunction and other risks.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Flurbiprofen, the active ingredient in Flugalin, primarily focuses on systemic effects observed with excessive exposure to this Nonsteroidal Anti-inflammatory Drug (NSAID). Documented overdose presentations may include central nervous system (CNS) manifestations such as change in consciousness, confusion, and unusual drowsiness. Gastrointestinal (GI) signs like nausea, vomiting, and abdominal pain are also officially noted.

Regulators emphasize the potential for severe or life-threatening outcomes that require immediate intervention. These include serious GI complications such as bleeding or perforation, acute renal failure, and the NSAID class risk for arterial thrombotic events (e.g., heart attack or stroke).

Immediate medical attention is required for any suspected overdose or for the occurrence of severe symptoms, including chest pain, sudden weakness or numbness, or trouble breathing. Regulatory guidance mandates that treatment is symptomatic and supportive. No specific antidote is known for Flurbiprofen overdose. Monitoring in a clinical setting is necessary to address potential complications and may involve procedures like gastric lavage or administration of activated charcoal in appropriate circumstances.

Therapeutic Uses of Flugalin

Main Uses of Flugalin

Flugalin, which contains the active substance flurbiprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is primarily used to manage pain, reduce inflammation, and lower fever associated with various musculoskeletal and inflammatory conditions.

Inflammatory Joint Conditions

The medication is frequently used for the long-term symptomatic treatment of chronic inflammatory joint diseases. These include:

  • Rheumatoid Arthritis: A condition where the immune system attacks the joints, causing pain and swelling.
  • Osteoarthritis: A degenerative joint disease resulting from the breakdown of joint cartilage and underlying bone.
  • Ankylosing Spondylitis: A type of arthritis that primarily affects the spine, leading to severe inflammation and potential fusion of the vertebrae.

Acute Musculoskeletal Disorders

Flugalin is also effective for the short-term management of acute conditions affecting the muscles, tendons, and ligaments, such as:

  • Frozen Shoulder (Capsulitis): Inflammation of the shoulder capsule that causes pain and stiffness.
  • Bursitis and Tendonitis: Inflammation of the fluid-filled sacs (bursae) or tendons, often resulting from repetitive strain or injury.
  • Soft Tissue Injuries: Management of pain and swelling following sprains or strains.

Pain Management

Beyond chronic conditions, the medication is used to provide relief for various types of mild to moderate pain, including:

  • Post-operative Pain: Management of discomfort following surgical procedures.
  • Dysmenorrhea: Relief from painful menstrual cramps.
  • Dental Pain: Alleviation of pain following dental work or due to inflammatory dental conditions.

Benefits of Treatment

The primary benefit of Flugalin is the reduction of prostaglandins, chemicals in the body that signal pain and promote inflammation. By inhibiting the production of these chemicals, the medication helps to:

  • Reduce Swelling: Decrease joint and tissue edema, which can improve physical appearance and comfort.
  • Increase Mobility: By easing pain and stiffness, it can help individuals maintain better range of motion in affected joints.
  • Improve Daily Function: Reducing chronic or acute pain allows for easier performance of routine daily activities.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Eligibility for Flugalin (Flurbiprofen oromucosal spray) is strictly defined by regulatory documents, primarily governing use based on age, physiological status, and pre-existing medical conditions. The medicine is formally approved for use only by adults aged 18 years and over. It is formally contraindicated (must not be used) for all children and adolescents below this age, as safety and efficacy are not established in this population.

Several health conditions define non-eligibility. Use is absolutely contraindicated if there is a known hypersensitivity to flurbiprofen, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or if a patient has severe heart failure, severe renal failure, or severe hepatic failure. Individuals with a history of active or recurrent peptic ulcers or gastrointestinal haemorrhage must also not use this product.

Regarding reproductive status, Flugalin is contraindicated during the last trimester of pregnancy and is not recommended during the first two trimesters or while breastfeeding. Specific populations, such as the elderly and those with mild to moderate organ impairment, require caution, with use officially mandated to be limited to the shortest duration possible.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Flugalin (Flurbiprofen) is officially defined by regulatory restrictions relating to its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Combinations to Avoid or Use with Restriction

Co-administration is prohibited with other NSAIDs, including COX-2 selective inhibitors, and high-dose Acetylsalicylic Acid (Aspirin) due to an officially documented increased risk of severe gastrointestinal adverse effects.

Pharmacodynamic and Exposure-Altering Interactions

Flugalin is documented to interact with medicines that affect coagulation. Use with Anticoagulants (such as Warfarin) and Anti-platelet Agents may enhance their pharmacodynamic effects, significantly increasing the risk of serious hemorrhage. The drug's metabolism via the CYP2C9 enzyme can lead to pharmacokinetic interactions. Furthermore, Flurbiprofen is officially documented to reduce the clearance of certain medicines, which may result in elevated serum concentrations of co-administered drugs like Lithium and Phenytoin.

Timing and Condition-Specific Constraints

Mandatory timing separation constraints apply to some combinations. Flurbiprofen must not be used for 8–12 days following Mifepristone administration. For Methotrexate, administration must be avoided within 24 hours before or after its dose to prevent toxic serum levels. Interactions with Antihypertensive Drugs carry an enhanced risk of nephrotoxicity, particularly in patients with compromised renal function. Furthermore, the co-ingestion of Alcohol may increase the risk of adverse reactions, including gastrointestinal bleeding.

Mechanism of Action

How Flugalin Works

The mechanism of action is defined by the chemical suppression of pro-inflammatory mediator biosynthesis, achieving a concentrated local effect.


Enzyme Cascade Blockade and Mediator Suppression

The core mechanism of action is the non-selective, reversible inhibition of the Cyclooxygenase ( COX-1 and COX-2) enzyme system. Inhibition of the enzyme catalytic site prevents the conversion of arachidonic acid into pro-inflammatory mediators, thereby reducing the rate of the inflammatory cascade.


Mechanism-to-Effect Causal Chain

The resulting reduction in PGE2 concentration produces two key physiological modulations within the local tissue. First, this action modulates the sensitization threshold of peripheral nerve endings, which reverses the prostaglandin-driven augmentation of nociceptive signaling. Second, the mechanism reverses the prostaglandin-mediated increase in vascular permeability, which decreases local fluid accumulation and associated tissue edema.


Mechanistic Specificity and Onset

The oromucosal spray formulation supports the rapid, localized penetration of Flurbiprofen directly into the pharyngeal tissue, which influences the kinetics of the mechanism. The localized action concentrates the enzyme blockade and the resulting modulation of inflammatory mediators within the target tissues.

Dosage and Administration Information

How to Use Flugalin

This section outlines the standardized administration protocol for Flugalin (Flurbiprofen oromucosal spray).


Administration Scope and Technique

Flugalin is intended for topical administration via the oromucosal route, meaning the product is applied directly to the throat mucosa. The administration of the medicine is not dependent on mealtimes, as the product is delivered to the pharynx, not the digestive tract.

To ensure correct delivery of the single, metered dose of 8.75 mg Flurbiprofen, the spray pump must be primed (typically four actuations) before the first use of a new container or following a prolonged period of non-use. The user must direct the actuation to the back of the throat while actively avoiding inhalation of the product during administration.


Standard Dosing and Duration

Administration of the single 8.75 mg dose is intended for use only as needed for acute, localized symptoms. The use pattern is time-bound and symptom-dependent.

Administration Feature Official Instruction
Dosing Frequency One dose every 3 to 6 hours
Maximum Daily Use 5 doses (actuations) in a 24-hour period
Maximum Duration Short-term use only, not to exceed 3 consecutive days

Population-Specific Rules

Standard protocols impose limitations on use in specific age groups. Flugalin is not recommended for use in children and adolescents under 12 years of age. For older adults, the protocol requires utilizing the lowest effective dose for the shortest time necessary.

Recent Clinical Evidence

Research Evidence for Flugalin (Flurbiprofen Oromucosal Spray)

This overview summarizes the research structure—the types of studies, outcomes, and populations evaluated—that forms the research base for Flugalin. This information is based on research that explores how patient-reported symptoms change over time.


Research Scenarios: Acute Sore Throat and Pharyngitis

Research primarily involved multiple, short-term Randomized Controlled Trials (RCTs). Many were conducted using a double-blind, placebo-controlled design, which is standard for research that examines patient-reported experiences. These trials included adults with acute sore throat, often due to Upper Respiratory Tract Infections (URTIs).

Key outcomes monitored included tracking shifts in patient-reported pain intensity and evaluating changes in difficulty swallowing, which is a functional measure. Findings describe patterns observed in the studied groups during periods of heightened symptom activity.


Research Scenarios: Symptoms Monitored Following Surgical Procedures

There is a smaller body of research that examined patient-reported experiences in certain surgical settings. These studies focused on adult patients recovering from specific ear, nose, and throat (ENT) interventions. Research monitored changes in throat pain intensity and the severity of hoarseness in the immediate postoperative period. The research structure is narrowly focused, meaning the results apply only to the specific surgical populations studied.


⌛ Follow-up Duration and Long-Term Research Gaps

Clinical trials have primarily focused on research exploring short-term symptom changes. The duration of observation in single-dose studies was typically limited to the first few hours after application, and studies involving repeated applications observed responses over defined time intervals up to three days. Long-term outcomes are not fully established, as follow-up durations were limited in the core trials.


‍‍ Inclusion Status of Specific Patient Populations

Data for certain groups remain insufficient, as core studies exploring changes measured during the study period focused predominantly on adults (18 years and older). There is limited information regarding how this product was evaluated in children or adolescents. Similarly, dedicated clinical trials specifically examining outcomes for the older adult age group or for patients with complex underlying medical conditions are not extensive in the regulatory evidence summaries.


What Remains Unstudied or Uncertain in the Research Landscape

Several areas remain uncharacterized or less certain. Long-term outcomes are not fully established, as follow-up durations were limited. Additionally, research exploring longer-term episodic or fluctuating symptom manifestations is limited. Comparative evidence with every other type of localized sore throat treatment is also not consistently available across the entire body of research.

Key Studies & References

  1. Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial
  2. Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation
  3. Flurbiprofen Geiser 8,75 mg oromucosal spray, solution - Annex I-II-III (EMA/CHMP Scientific Assessment)

Frequently Asked Questions (FAQ)

Common questions about Flugalin (FAQ)

Q: How long does the therapeutic effect of one dose of Flugalin typically last?

A: Studies and official information indicate that symptomatic reduction and pain relief from a single dose of Flugalin has been observed to last for up to six hours. This duration is consistent with the general time interval provided in the product information.

Q: How often do common side effects like headache or nausea occur with Flugalin?

A: According to the official product information, common side effects such as anxiety or nervousness are reported to occur in approximately 1% to 10% of patients in clinical settings. This frequency is based on data collected during the product's trials and licensing process.

Q: Are there any specific foods or drinks that should be avoided when taking Flugalin?

A: Official product information notes that combining the medication with alcohol may increase the documented risk of serious adverse reactions, such as gastrointestinal bleeding. Beyond alcohol, no specific food avoidance is routinely required for this medication.

Q: How does the mechanism of Flugalin work inside the body in simple, non-technical terms?

A: Flugalin works by temporarily blocking the production of certain natural substances within the body that cause inflammation and pain signals at the site of the sore throat. This action helps to reduce both the feeling of pain and the underlying inflammation and swelling.

Q: Is it safe to take popular over-the-counter cold and flu remedies with Flugalin?

A: Official documents warn that Flugalin, which is classified as an NSAID, should not be combined with other NSAID medicines. Because many popular over-the-counter cold and flu remedies contain NSAIDs, a review of the ingredient list is advised to help avoid an increased risk of serious adverse effects.

Q: Why do some people experience trouble sleeping when taking Flugalin?

A: Regulatory documents indicate that two distinct central nervous system effects are possible: somnolence (drowsiness) and insomnia (difficulty falling asleep or staying asleep). This information, which covers both effects, is included in the official safety profile for the medication.

Q: Can I take caffeine products, like coffee or tea, while on Flugalin?

A: Official labeling does not contain a specific dedicated warning against the use of caffeine products like coffee or tea. However, regulatory documents advise patients to inform their healthcare providers about all supplements and herbs taken.

Q: Is it normal for the effects of Flugalin to fade before the next dose is due?

A: The official dosing schedule provides an interval of 3 to 6 hours between doses. This time frame suggests that symptom relief is not intended to last beyond six hours, and it is consistent with the product's therapeutic window for the effects to begin fading.

Q: Are there any specific genetic factors that affect how Flugalin works?

A: Official documentation confirms that the drug is broken down in the body via the CYP2C9 enzyme pathway. Regulatory text recognizes that the function of this enzyme can be influenced by certain natural genetic variations among individuals, which may impact how the body processes the medication.

Q: Is Flugalin classified as a controlled substance or known to be habit-forming?

A: According to regulatory sources, the active ingredient, Flurbiprofen, is not listed as a controlled substance by major government authorities. It is therefore not associated with dependency or the need for special monitoring required by scheduled drugs.

Q: What is the difference between the brand name and the generic version of Flugalin?

A: The generic version contains the identical active ingredient, Flurbiprofen, as the brand-name product. Regulatory agencies require that generic medicines meet the same high government standards for quality, strength, performance, and route of administration as the original product.

Q: What should be done if a side effect of Flugalin seems to be too bothersome or severe?

A: Official patient safety information advises that if a side effect seems severe or causes distress, patients should stop using the product and seek immediate medical assistance. This instruction applies particularly to serious symptoms such as swelling, trouble breathing, or chest pain.

Q: Can vitamins or dietary supplements interfere with the way Flugalin works?

A: Official labeling states that potential interactions can occur between Flugalin and other products. For this reason, regulatory documents advise patients to tell their healthcare provider about all medicines, including vitamins and herbal supplements.

Q: Is it normal to feel a change in appetite when first starting Flugalin?

A: According to the official side effect reporting, loss of appetite (anorexia) is listed as a possible adverse reaction associated with the medication. This information suggests that feeling a change in appetite when starting the medication is a known possibility.

Q: Can Flugalin cause changes in mood or emotional state?

A: Official side effect reporting confirms that changes in mood and emotional state are possible adverse reactions. These reported effects include feelings of nervousness, anxiety, and depression.

Q: Is there a general rule about what to do if a dose of Flugalin is accidentally missed?

A: According to the official patient instructions for missed doses, the general rule is to take the dose as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. The regulatory instruction is not to take two doses at the same time.

Q: Can Flugalin cause weight gain or weight loss in patients?

A: Official side effect reporting includes both weight gain and weight loss as possible adverse reactions associated with the medication.

Q: What official information is available about potential dependency or withdrawal symptoms with Flugalin?

A: Official information regarding its classification confirms that Flurbiprofen is not associated with dependency or the severe withdrawal symptoms that require specific monitoring for controlled substances.

Q: Is there a risk of overdose with Flugalin, and what are the general signs?

A: Regulatory information indicates there is a risk of overdose. If overdose is suspected, immediate medical attention is instructed. General signs that may be observed include drowsiness, loss of consciousness, shallow breathing, chest pain, and severe headache.

Q: Why is Flugalin only available with a doctor's prescription?

A: According to the official classification, the medicine is available only with a prescription due to the documented risk of serious, rare adverse effects. These include serious cardiovascular events (such as heart attack or stroke) and major gastrointestinal issues (such as stomach bleeding).

Q: How long after stopping Flugalin does the medicine generally stay in the body's system?

A: Studies and official pharmacokinetic (PK) data show that the half-life of Flurbiprofen is approximately 3 to 4 hours. This means it generally takes about 15 to 20 hours (five half-lives) for the drug to be almost entirely cleared from the body’s system.

Q: What information exists about using herbal remedies alongside Flugalin?

A: Regulatory labeling advises patients to tell their doctor or pharmacist about all medicines, including vitamins and herbal supplements. This advice is given because potentially harmful interactions may occur between the medicine and other remedies.

Q: What is the general information about the use of Flugalin in relation to having surgery?

A: Official regulatory warnings state that Flurbiprofen must not be used just before or after a specific type of heart bypass surgery (Coronary Artery Bypass Graft, or CABG). This restriction is in place because of the documented increased risk of fatal cardiovascular events associated with this drug class in that setting.

How should Flugalin be stored and disposed of?

How to Store and Dispose of Flugalin

Storage and disposal of Flugalin (Flurbiprofen oromucosal spray) must strictly follow official regulatory instructions to maintain the product’s integrity and safety.

Detail Official Regulatory Requirement
Storage Temperature Store below 30 C (Controlled Room Temperature)
Prohibited Environment Do not refrigerate or freeze
Protection Requirement Protect from light; keep in the original container
Post-Opening Stability Shelf-life after first opening: 6 months
Child Safety Keep out of the sight and reach of children
Disposal Instructions Dispose of unused product according to local pharmaceutical waste requirements

The regulatory profile requires that the product be kept below 30 C and protected from light, with explicit instructions not to freeze or refrigerate the solution. The container must be kept tightly closed. For stability, the medicine must be discarded after six months once the bottle has been opened. Disposal must follow local regulations for pharmaceutical waste and must not be done via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flugalin found in:

A-Z Index: